November 18, 2026
Health news, explained with evidence
LIVE

Statin Trial for Compensated Cirrhosis Shows Hint of Benefit but Misses Statistical Significance

🔬 Research 2 min read 👁 2

A phase III study found simvastatin reduced liver decompensation and cancer events in high-risk cirrhosis patients, though the result fell just short of statistical significance. Researchers say statins remain safe and should not be withheld when indicated.

Statin Trial for Compensated Cirrhosis Shows Hint of Benefit but Misses Statistical Significance🔬Research

Photo: medpagetoday.com

Key points

  • Simvastatin reduced decompensation and liver cancer events by 59% vs placebo, but P=0.064.
  • No significant difference in overall survival; safety profile favored statin.
  • HCC incidence was notably lower in the statin group (2.6% vs 7.8%).

A phase III trial testing daily simvastatin in patients with compensated cirrhosis reported a 59% relative reduction in hepatic decompensation or liver cancer compared with placebo, but the difference narrowly missed statistical significance (hazard ratio 0.41, 95% CI 0.16–1.05, P=0.064). The SACRED study, presented at the American Association for the Study of Liver Diseases annual meeting, enrolled patients at 11 VA medical centers who had high-risk features such as esophageal varices, low platelet counts, or advanced liver stiffness.

Safety and secondary findings

Overall survival did not differ significantly between groups, and adverse event rates were similar. Serious adverse events and liver-related events actually occurred less often in the statin arm. Notably, hepatocellular carcinoma developed in 2.6% of statin recipients versus 7.8% of placebo patients, the largest numerical difference observed. A restricted mean survival time analysis showed a significant 51-day advantage for simvastatin, though the lead investigator urged caution in interpreting that result.

Limitations and context

The trial was limited by a small sample size and lower-than-expected event rates, partly because many eligible patients were already on statins or had standard indications and were excluded. Observational studies have previously linked statins to lower decompensation and mortality in cirrhosis, but randomized trials have been inconsistent. An ongoing study of rosuvastatin may help clarify the picture.

Statins are safe for patients with cirrhosis and shouldn't be withheld from those who have indications.

What to know: Current evidence suggests statins do not harm patients with cirrhosis and may reduce liver-related complications, but definitive proof is lacking. Patients should discuss statin use with their clinician based on individual cardiovascular and liver risk.

Source medpagetoday.com — medpagetoday.com/meetingcoverage/aasld/123877 ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.